AUPH Stock Analysis: Aurinia Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.007m USD | 12M Return: 117.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 26.8M
Qual. Beats: 3
Rev. Trend: 99.1%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) is a Canada-based biopharmaceutical company founded in 1993 and headquartered in Edmonton, focused on developing and commercializing therapies for autoimmune diseases with high unmet medical needs, primarily in the United States and Japan. The companys lead commercial product is LUPKYNIS (voclosporin), an oral therapy approved for the treatment of adult patients with active lupus nephritis, a serious kidney inflammation associated with systemic lupus erythematosus (SLE). In addition, Aurinia is developing aritinercept, a dual inhibitor targeting B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL), which are cytokines involved in B-cell mediated autoimmune responses.
As a mid-cap biotechnology company with a market capitalization of approximately $2.2 billion USD, Aurinia operates in a sector characterized by high research and development costs, long product development cycles, and significant reliance on a small number of commercialized assets. The companys business model is heavily dependent on the commercial success of LUPKYNIS, which exposes it to concentration risk typical of single-product biopharmas, while its pipeline development in autoimmune disease targets specialty indications that often qualify for orphan drug designation and premium pricing in the U.S. and Japanese markets.
- LUPKYNIS sales traction in active lupus nephritis patients
- Voclosporin patent protection timeline limits generic erosion risk
- Aritinercept clinical readouts expand autoimmune pipeline optionality
| Net Income: 298.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.23 > 0.02 and ΔFCF/TA 10.19 > 1.0 |
| NWC/Revenue: 132.0% < 20% (prev 136.4%; Δ -4.44% < -1%) |
| CFO/TA 0.23 > 3% & CFO 165.8m > Net Income 298.2m |
| Net Debt (-310.1m) to EBITDA (161.8m): -1.92 < 3 |
| Current Ratio: 5.55 > 1.5 & < 3 |
| Outstanding Shares: last quarter (137.6m) vs 12m ago -0.92% < -2% |
| Gross Margin: 89.74% > 18% (prev 88.24%; Δ 1.50% > 0.5%) |
| Asset Turnover: 48.55% > 50% (prev 48.98%; Δ -0.44% > 0%) |
| Interest Coverage Ratio: 14.61 > 6 (EBIT TTM 142.4m / Interest Expense TTM 9.74m) |
| A: 0.54 (Total Current Assets 480.2m - Total Current Liabilities 86.6m) / Total Assets 724.0m |
| B: -0.85 (Retained Earnings -615.0m / Total Assets 724.0m) |
| C: 0.23 (EBIT TTM 142.4m / Avg Total Assets 614.4m) |
| D: 3.63 (Book Value of Equity 567.6m / Total Liabilities 156.4m) |
| Altman-Z'' = 6.17 = AAA |
| DSRI: 1.01 (Receivables 49.2m/40.4m, Revenue 298.3m/247.3m) |
| GMI: 0.98 (GM 88.24% / 89.74%) |
| AQI: 23.88 (AQ_t 0.24 / AQ_t-1 0.01) |
| SGI: 1.21 (Revenue 298.3m / 247.3m) |
| TATA: 0.18 (NI 298.2m - CFO 165.8m) / TA 724.0m) |
| Beneish M = 10.70 (Cap -4..+1) = D |
As of July 08, 2026, the stock is trading at USD 16.22 with a total of 2,343,115 shares traded. Over the past week, the price has changed by -3.39%, over one month by +3.58%, over three months by +2.72% and over the past year by +117.14%.
Current recommended Stop Loss: 14.40 (which is 11.2% or 2.2 ATR below the current price).
Aurinia Pharmaceuticals has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy AUPH.
- StrongBuy: 3
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 17 | 4.8% |
P/E Trailing = 7.2269
P/E Forward = 18.1159
P/S = 6.7298
P/B = 3.5366
Revenue TTM = 298.3m USD
EBIT TTM = 142.4m USD
EBITDA TTM = 161.8m USD
Long Term Debt = 50.5m USD (estimated: total debt 68.6m - short term 18.1m)
Short Term Debt = 18.1m USD (from shortTermDebt, last quarter)
Debt = 68.6m USD (from shortLongTermDebtTotal, last quarter) (leases 68.6m already included)
Net Debt = -310.1m USD (calculated: Debt 68.6m - CCE 378.8m)
Enterprise Value = 1.70b USD (2.01b + Debt 68.6m - CCE 378.8m)
Interest Coverage Ratio = 14.61 (Ebit TTM 142.4m / Interest Expense TTM 9.74m)
EV/FCF = 10.25x (Enterprise Value 1.70b / FCF TTM 165.5m)
FCF Yield = 9.75% (FCF TTM 165.5m / Enterprise Value 1.70b)
FCF Margin = 55.50% (FCF TTM 165.5m / Revenue TTM 298.3m)
Net Margin = 99.97% (Net Income TTM 298.2m / Revenue TTM 298.3m)
Gross Margin = 89.74% ((Revenue TTM 298.3m - Cost of Revenue TTM 30.6m) / Revenue TTM)
Gross Margin QoQ = 91.63% (prev 89.01%)
Tobins Q-Ratio = 2.34 (Enterprise Value 1.70b / Total Assets 724.0m)
Interest Expense / Debt = 14.19% (Interest Expense 9.74m / Debt 68.6m)
Taxrate = 21.79% (9.57m / 43.9m)
NOPAT = 111.4m (EBIT 142.4m * (1 - 21.79%))
Current Ratio = 5.55 (Total Current Assets 480.2m / Total Current Liabilities 86.6m)
Debt / Equity = 0.12 (Debt 68.6m / totalStockholderEquity, last quarter 567.6m)
Debt / EBITDA = -1.92 (Net Debt -310.1m / EBITDA 161.8m)
Debt / FCF = -1.87 (Net Debt -310.1m / FCF TTM 165.5m)
Total Stockholder Equity = 462.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 48.54% (Net Income 298.2m / Total Assets 724.0m)
RoE = 64.48% (Net Income TTM 298.2m / Total Stockholder Equity 462.5m)
RoCE = 27.75% (EBIT 142.4m / Capital Employed (Equity 462.5m + L.T.Debt 50.5m))
RoIC = 17.38% (NOPAT 111.4m / Invested Capital 640.7m)
WACC = 8.07% (E(2.01b)/V(2.08b) * Re(7.97%) + D(68.6m)/V(2.08b) * Rd(14.19%) * (1-Tc(0.22)))
Discount Rate = 7.97% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -42.22 | Cagr: -1.94%
[DCF] Terminal Value 77.97% ; FCFF base≈124.9m ; Y1≈143.2m ; Y5≈210.8m
[DCF] Fair Price = 27.07 (EV 3.17b - Net Debt -310.1m = Equity 3.48b / Shares 128.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 2.99 | # QB: 3
Revenue Correlation: 99.11 | Revenue CAGR: 26.98% | SUE: 0.22 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.25 | Chg30d=+12.50% | Revisions=+25% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.24 | Chg30d=+15.48% | Revisions=+25% | Analysts=4
EPS current Year (2026-12-31): EPS=0.96 | Chg30d=+14.97% | Revisions=+25% | GrowthEPS=-53.6% | GrowthRev=+14.6%
EPS next Year (2027-12-31): EPS=1.12 | Chg30d=+33.89% | Revisions=+25% | GrowthEPS=+16.5% | GrowthRev=+19.3%
[Analyst] Revisions Ratio: +57% (up=4, down=0)